GeoVax Labs (NASDAQ:GOVX) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of GeoVax Labs (NASDAQ:GOVX) to a strong sell rating in a report published on Saturday morning.

Several other equities analysts have also recently commented on the company. D. Boral Capital reduced their target price on GeoVax Labs from $225.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, GeoVax Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.50.

GeoVax Labs Trading Up 4.9%

Shares of NASDAQ:GOVX opened at $2.99 on Friday. The company has a 50 day moving average of $7.48 and a 200 day moving average of $13.33. The stock has a market cap of $3.59 million, a P/E ratio of -0.08 and a beta of 3.67. GeoVax Labs has a 12 month low of $2.61 and a 12 month high of $57.50.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, November 13th. The company reported ($7.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. On average, equities analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Sabby Management LLC purchased a new position in shares of GeoVax Labs during the third quarter worth approximately $313,000. Armistice Capital LLC bought a new stake in GeoVax Labs in the third quarter worth $253,000. Hudson Bay Capital Management LP purchased a new stake in GeoVax Labs during the third quarter valued at about $47,000. Finally, Jane Street Group LLC bought a new position in shares of GeoVax Labs during the first quarter valued at about $27,000. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.